🇺🇸 FDA
Patent

US 11642364

Exon skipping oligomer conjugates for muscular dystrophy

granted A61KA61K31/712A61K31/7125

Quick answer

US patent 11642364 (Exon skipping oligomer conjugates for muscular dystrophy) held by Sarepta Therapeutics, Inc. expires Mon May 04 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Sarepta Therapeutics, Inc.
Grant date
Tue May 09 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 04 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
10
CPC classes
A61K, A61K31/712, A61K31/7125, A61K47/645, A61P